Alzheimers Commercial 2025

Alzheimers Commercial 2025

Alzheimers Commercial 2025. Abbvie is strengthening its neurology portfolio with a $1.4 billion acquisition of aliada therapeutics. New commercial arts, with charity client alzheimer’s society, have launched a platform and campaign bringing to life the devastating reality that with dementia you don’t just die once, you die again, again, and again.


Alzheimers Commercial 2025

In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of lecanemab and donanemab, coupled with rapid advancements to enable presymptomatic diagnosis, reinvigorating the space with new targets,. Our new advert ‘the long goodbye’ tells the unvarnished truth about the devastation caused by dementia.

Alzheimers Commercial 2025 Images References :